CELEX: 32019M9540
Language: en
Date: 2019-11-27 00:00:00
Title: Commission Decision of 27/11/2019 declaring a concentration to be compatible with the common market (Case No COMP/M.9540 - PERMIRA / CAMBREX) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

EUROPEAN COMMISSION
                                                                Brussels, 27.11.2019
                                                                C(2019) 8720 final
                                                                                 PUBLIC VERSION
                                                                To the notifying party
Subject:        Case M.9540 – Permira/Cambrex
                Commission decision pursuant to Article 6(1)(b) of Council Regulation
                                       1
                (EC) No 139/2004 and Article 57 of the Agreement on the European
                                    2
                Economic Area
Dear Sir or Madam,
1.      On 04 November 2019, the European Commission received notification of a proposed
        concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of
        the Merger Regulation by which the undertaking Permira Holdings Limited (United
        Kingdom) acquires within the meaning of Article 3(1)(b) of the Merger Regulation
        sole control over the whole of the undertaking Cambrex Corporation (United States of
        America) by way of purchase of shares.3
2.      The business activities of the undertakings concerned are:
             for Permira Holdings Limited: long-term private equity investments in companies
              active in a wide variety of sectors, including in the area of pharmaceutical
              contract development and manufacturing where Permira Holdings Limited
              controls two companies, Lyophilization Services of New England (LSNE) and
              Quotient Sciences; and
             for Cambrex Corporation: pharmaceutical contract development and
              manufacturing providing drug substance, drug product, and analytical services.
1       OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’). With effect from 1 December 2009, the Treaty on
        the Functioning of the European Union (‘TFEU’) has introduced certain changes, such as the
        replacement of ‘Community’ by ‘Union’ and ‘common market’ by ‘internal market’. The terminology
        of the TFEU will be used throughout this decision.
2       OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).
3       Publication in the Official Journal of the European Union No C 379, 08.11.2019, p. 7.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.
 ---pagebreak--- 3. After examination of the notification, the European Commission has concluded that
   the notified operation falls within the scope of the Merger Regulation and of
   paragraph 5(c) of the Commission Notice on a simplified procedure for treatment of
   certain concentrations under Council Regulation (EC) No 139/2004.4
4. For the reasons set out in the Notice on a simplified procedure, the European
   Commission has decided not to oppose the notified operation and to declare it
   compatible with the internal market and with the EEA Agreement. This decision is
   adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of
   the EEA Agreement.
                                                  For the Commission
                                                  (Signed)
                                                  Cecilio MADERO VILLAREJO
                                                  Acting Director-General
4  OJ C 366, 14.12.2013, p. 5.
                                              2